Floatz logo

Inotuzumab Ozogamicin

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Institute of Hematology & Blood Diseases Hospital, Chinaantibody_drug_conjugatePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
81/ 100

Competitive context

19 Active assets in the Precursor Cell Lymphoblastic Leukemia-Lymphoma cohort.

Asset / SponsorPhaseRating
LIDOCAINE
CAMC Health System
Phase 4BB
DEXAMETHASONE
Institute of Hematology & Blood Diseases Hospital, China
Phase 2B
Cyclophosphamide
Institute of Hematology & Blood Diseases Hospital, China
Phase 2B
ETOPOSIDE
Asan Medical Center
Phase 2B
MERCAPTOPURINE ANHYDROUS
Institute of Hematology & Blood Diseases Hospital, China
Phase 2B

View all 33 →

Same molecule, other indications

Inotuzumab Ozogamicin is also rated in:

acute lymphoblastic leukemiaDormant
BB
Indicative ·
69 / 100
View asset →
B-cell acute lymphoblastic leukemiaDormant
BB
Indicative ·
68 / 100
View asset →
B Lymphoblastic LymphomaDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →